Literature DB >> 23446496

Effect of the levonorgestrel intrauterine device on genital HIV-1 RNA shedding among HIV-1-infected women not taking antiretroviral therapy in Nairobi, Kenya.

Jenell S Coleman1, Christina Mwachari, Jennifer Balkus, Lucy Sanguli, Angela Muliro, Kathy Agnew, Robert W Coombs, Craig R Cohen, Jane Hitti.   

Abstract

The effect of the levonorgestrel-releasing intrauterine device (LNG-IUD) on genital HIV-1 RNA shedding and inflammation among 25 HIV-infected women was evaluated. Blood, endocervical, and cervicovaginal lavage samples were collected from HIV-infected women not taking antiretrovirals before LNG-IUD insertion and 1 month, 3 month, and 6 months thereafter. HIV-1 RNA was quantitated by real-time reverse transcriptase-polymerase chain reaction. Inflammatory markers were measured by enzyme immunoassay. Genital HIV-1 RNA shedding and inflammatory markers did not differ between LNG-IUD placement and month 6, with the exception of interleukin 1β that increased (0.42 log10; 95% confidence interval: 0.10 to 0.75). The LNG-IUD did not increase genital HIV-1 RNA shedding after 6 months of use.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23446496      PMCID: PMC3668353          DOI: 10.1097/QAI.0b013e31828decf8

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  18 in total

1.  Effect of intrauterine device use on cervical shedding of HIV-1 DNA.

Authors:  B A Richardson; C S Morrison; C Sekadde-Kigondu; S K Sinei; J Overbaugh; D D Panteleeff; D H Weiner; J K Kreiss
Journal:  AIDS       Date:  1999-10-22       Impact factor: 4.177

2.  Removal of an intrauterine device and the treatment of acute pelvic inflammatory disease.

Authors:  K Teisala
Journal:  Ann Med       Date:  1989-02       Impact factor: 4.709

3.  Variation of human immunodeficiency virus type 1 viral RNA levels in the female genital tract: implications for applying measurements to individual women.

Authors:  R W Coombs; D J Wright; P S Reichelderfer; D N Burns; J Cohn; S Cu-Uvin; P A Baron; M H Cohen; A L Landay; S Lewis; A Kovacs
Journal:  J Infect Dis       Date:  2001-09-13       Impact factor: 5.226

4.  Influence of an intrauterine device on the course of an acute salpingitis.

Authors:  G Söderberg; S Lindgren
Journal:  Contraception       Date:  1981-08       Impact factor: 3.375

5.  Influence of sex hormones, HIV status, and concomitant sexually transmitted infection on cervicovaginal inflammation.

Authors:  Khalil G Ghanem; Nina Shah; Robert S Klein; Kenneth H Mayer; Jack D Sobel; D L Warren; Denise J Jamieson; Ann C Duerr; Anne M Rompalo
Journal:  J Infect Dis       Date:  2004-12-28       Impact factor: 5.226

6.  Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation.

Authors:  R P Nugent; M A Krohn; S L Hillier
Journal:  J Clin Microbiol       Date:  1991-02       Impact factor: 5.948

7.  Investigation of a copper-intrauterine device (Cu-IUD) for possible effect on frequency and healing of pelvic inflammatory disease.

Authors:  B Larsson; M Wennergren
Journal:  Contraception       Date:  1977-02       Impact factor: 3.375

Review 8.  Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties.

Authors:  T Luukkainen; J Toivonen
Journal:  Contraception       Date:  1995-11       Impact factor: 3.375

9.  Intrauterine devices and pelvic inflammatory disease: an international perspective.

Authors:  T M Farley; M J Rosenberg; P J Rowe; J H Chen; O Meirik
Journal:  Lancet       Date:  1992-03-28       Impact factor: 79.321

10.  Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial.

Authors:  K Andersson; V Odlind; G Rybo
Journal:  Contraception       Date:  1994-01       Impact factor: 3.375

View more
  4 in total

1.  A systematic review of contraceptive continuation among women living with HIV.

Authors:  Catherine S Todd; Tracy C Anderman; Sarah Long; Landon Myer; Linda-Gail Bekker; Gregory A Petro; Heidi E Jones
Journal:  Contraception       Date:  2018-02-09       Impact factor: 3.375

Review 2.  Drug-Drug Interactions, Effectiveness, and Safety of Hormonal Contraceptives in Women Living with HIV.

Authors:  Kimberly K Scarsi; Kristin M Darin; Catherine A Chappell; Stephanie M Nitz; Mohammed Lamorde
Journal:  Drug Saf       Date:  2016-11       Impact factor: 5.606

3.  Safety and continued use of the levonorgestrel intrauterine system as compared with the copper intrauterine device among women living with HIV in South Africa: A randomized controlled trial.

Authors:  Catherine S Todd; Heidi E Jones; Nontokozo Langwenya; Donald R Hoover; Pai-Lien Chen; Gregory Petro; Landon Myer
Journal:  PLoS Med       Date:  2020-05-22       Impact factor: 11.069

4.  Impact of etonogestrel implant use on T-cell and cytokine profiles in the female genital tract and blood.

Authors:  Lisa B Haddad; Alison Swaims-Kohlmeier; C Christina Mehta; Richard E Haaland; Nakita L Brown; Anandi N Sheth; Hsin Chien; Kehmia Titanji; Sharon L Achilles; Davis Lupo; Clyde E Hart; Igho Ofotokun
Journal:  PLoS One       Date:  2020-03-26       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.